Alector Inc. (ALEC)
1.47
-0.17 (-10.37%)
At close: Mar 03, 2025, 11:32 AM
No 1D chart data available
| Bid | 1.46 |
| Market Cap | 145.16M |
| Revenue (ttm) | 62.31M |
| Net Income (ttm) | -160.47M |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -1.19 |
| Forward PE | -1 |
| Analyst | Buy |
| Ask | 1.47 |
| Volume | 1,178,933 |
| Avg. Volume (20D) | 1,038,203 |
| Open | 1.62 |
| Previous Close | 1.64 |
| Day's Range | 1.43 - 1.65 |
| 52-Week Range | 1.43 - 7.45 |
| Beta | 0.61 |
About ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, incl...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2019
Employees 238
Stock Exchange NASDAQ
Ticker Symbol ALEC
Website https://www.alector.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 207.17% from the latest price.
Buy 60.00%
Hold 20.00%
Sell 20.00%
Earnings Surprise
Alector has released their quartely earnings
on Feb 26, 2025:
Next Earnings Release
Alector Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-13.1%
Alector shares are trading lower after the company...
Unlock content with
Pro Subscription
3 months ago
-35.1%
Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.
